Aclidinium bromide
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Aclidinium bromide?
Summarize this article for a 10 year old
Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States on July 24, 2012[2] as a maintenance treatment for chronic obstructive pulmonary disease (COPD).[3]
Clinical data | |
---|---|
Trade names | Bretaris Genuair, Eklira Genuair, Tudorza Pressair |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Inhalation |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | <5% (in system) 30% (in lung) |
Metabolism | Ester hydrolysis |
Elimination half-life | 2–3 hrs |
Duration of action | >24 hrs |
Excretion | 65% urine, 33% feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.260.213 |
Chemical and physical data | |
Formula | C26H30BrNO4S2 |
Molar mass | 564.55 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD.[4] However, it does not appear to affect the risk of death or the frequency steroids are needed.[4] It is unclear if it differs from the similar medication tiotropium or other commonly used medications from the class of LAMAs.[4]
Aclidinium is delivered via a multidose dry powder inhaler, the Genuair inhaler. It is on the World Health Organization's List of Essential Medicines.[5]